During the past decade, Semmelweis Egyetem I. sz. Belgyógyászati Klinika conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 4 clinical trials were completed, i.e. on average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Astex Pharmaceuticals, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Applied Molecular Transport" with 1 trials sponsored and "Aziende Chimiche Riunite Angelini Francesco S.p.A" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" #1 collaborator was "Chiltern International Inc." with 1 trials as a collaborator and "Pharmacyclics LLC." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" are "Acute Myeloid Leukemia" (1 trials), "Amyloidosis" (1 trials), "Chronic Graft Versus Host Disease" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Crohn's Disease" (1 trials). Many other conditions were trialed in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" in a lesser frequency.

Most popular intervention types in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" are "Drug" (15 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "AMT-101 (oral)-Dose A" (1 trials), "AMT-101 (oral)-Dose B" (1 trials), "ASTX660" (1 trials) and "Axitinib (AG-013736)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" are 14 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in Semmelweis Egyetem I. sz. Belgyógyászati Klinika, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Semmelweis Egyetem I. sz. Belgyógyászati Klinika, 4 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".